| Revenue growth | 11.6% YoY consolidated; 7% YoY standalone. |
|---|---|
| Margins | Consolidated EBITDA margin 14.5% vs 16.0% YoY; Standalone 18.4% vs 21.6% YoY. |
| Demand visibility | Strong, driven by surgery volumes and international patient growth (42% in international). |
| Management confidence | High; emphasizing global leadership in joint replacement. |
Growth
Consolidated revenue grew 11.6% YoY; EBITDA grew 0.9% to ₹490 mn. Standalone revenue grew 7.0% YoY to ₹2,591 mn.
Outlook
Targeting 40% additional bed capacity for organic growth; expansion plan focused on Mumbai hospitals; doubling ROCE via operational leverage.
Risks
EBITDA margins compressed YoY from 16.0% to 14.5% consolidated and 21.6% to 18.4% standalone.
Last quarter's promises, checked
Delivered
- Guided MedTech EBITDA turnaround → delivered ₹3.7 cr (= BEAT)
- Targeted new tax regime benefit → delivered 25% vs 35% rate (= BEAT)
- Guided International patient recovery → delivered 42% growth (= BEAT)
Partly delivered
- Targeted 15% sustainable CAGR → delivered 11.6% revenue growth (= PARTIAL)
- Guided occupancy north of 50% → delivered 48% (50% excl. Gurugram) (= PARTIAL)
Missed
- Guided gross margin maintenance → delivered 85% vs 90% (= MISS)
- Targeted consolidated EBITDA growth → delivered 0.9% vs 43.1% prev (= MISS)
- Guided ARPOB growth → delivered -2.1% YoY (= MISS)
Investor Presentation filed with NSE, NSE: SHALBY. Summary written with AI assistance from the document.
Shalby Ltd: key numbers
- Share price
- ₹147.12
- Market cap
- ₹1,589 Cr
- Revenue (annual)
- ₹1,141 Cr
- Net profit (annual)
- ₹37.39 Cr
- P/E (TTM)
- 40.4×Sector 57.8×
- Promoter holding
- 74.33%+0.00% QoQ
- FII holding
- 4.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalby Ltd
All →Shalby Management Change
Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.
Shalby Annual General Meeting
Shalby Limited held its 22nd Annual General Meeting on September 10, 2026. The meeting covered adoption of financial statements and appointment of a whole-time director.
Shalby Earnings Call Transcript: Key Takeaways
Shalby reported a modest 11.6% revenue growth with its MetLife business reaching EBITDA break-even, but hospital margins remain under pressure due to new doctor recruitments.
- Call
- Guides 20% growth
Shalby Q1 FY27 Results: Net Profit ₹10.5 Cr, Up 36.4% YoY
Shalby Ltd reported revenue from operations of ₹331.2 Cr (+11.7% YoY) and net profit of ₹10.5 Cr (+36.4% YoY) for Q1 FY27.
- Key figure
- Net profit ₹10.5 Cr · +36.4% YoY
Shalby Earnings Call: Key Takeaways
Shalby Limited reported Q4 FY26 consolidated revenue growth of 9.4% YoY. Key focus on MedTech turnaround with positive EBITDA and expansion in oncology services.
Shalby Earnings Call: Key Takeaways
Shalby delivered strong Q4 growth with EBITDA up 43.1% YoY, driven by operational efficiency and recovery in the implant business despite geopolitical headwinds in international segments.